Navigation Links
Alkylating in Medical News

Journal of Clinical Oncology Publishes TREANDA Study Demonstrating Significant Improvement in Overall Response and Progression-Free Survival in Chronic Lymphocytic Leukemia

...ylaxis, tumor lysis syndrome, skin reactions, and other malignancies. TREANDA has a unique chemical structure that is synthesized to combine an alkylating group and a purine-like benzimidazole component. Though the exact mechanism of action of TREANDA remains unknown, TREANDA may act in two distinct way...

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

...hocyte Infusion II-35 Hematological Cancer Drug Classes II-35 Hypomethylating Agents & Antimetabolites II-35 Bisphosphonates II-36 alkylating Agents and DNA-Damaging Agents II-36 DNA-Repair Enzyme Inhibitors II-36 Histone Deacetylase Inhibitor II-36 Immunomodulators II-36 Pro...

Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009

...age of 50. TRC102 is a small molecule inhibitor of base excision repair that improves the therapeutic index of commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in combination with pemetrexed (Alimta(R)) and as an i.v. agent in com...

Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma

...1-day cycle, for up to eight cycles. About TREANDA TREANDA is a novel treatment with a unique chemical structure that is synthesized to combine an alkylating group and a purine-like benzimidazole component. Though the exact mechanism of action of TREANDA remains unknown, TREANDA may act in two distinct ways...

Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma

...1-day cycle, for up to eight cycles. About TREANDA TREANDA is a novel treatment with a unique chemical structure that is synthesized to combine an alkylating group and a purine-like benzimidazole component. Though the exact mechanism of action of TREANDA remains unknown, TREANDA may act in two distinct ways...

The Cancer Genome Atlas reports first results, Johns Hopkins Kimmel Cancer Center collaborates

...ation makes brain cancer cells more responsive to anticancer drugs known as alkylating agents. While brain cancer patients with the MGMT alteration respond better to the commonly-used alkylating agent temozolomide, the new TCGA research found that treatment also appears...

Vion Reports 2008 Second Quarter and Six-Month Results

...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...

Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting

...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...

Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting

... developed by Abbott researchers to prevent DNA repair in cancer cells and increase the effectiveness of common cancer therapies such as radiation and alkylating agents. ABT-888 completed a Phase 0 trial for patients with refractory solid tumors and lymphoid malignancies, and has entered several Phase I trial...

Vion Pharmaceuticals to Appeal Nasdaq Delisting

...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...
Alkylating in Medical Technology

TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009

...d on cancer stem cells. TRC102 is a small molecule inhibitor of base excision repair that reverses resistance to commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in combination with pemetrexed (Alimta(R)) and as an intravenous agent ...

Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer

...body-drug conjugate was well-tolerated in cynomolgous monkeys and mouse models. The critical role of cleavable linkers for minor groove binding alkylating agent (MGBA) based antibody-drug conjugates (Abstract #1722) The effectiveness of a cleavable linker over a non-cleavable linker when used with MGB...

Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL

...B-CLL. Campath was initially approved in 2001 under accelerated approval regulations for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy. Campath was developed by Genzyme Corporation. Campath is marketed in the U.S. by Bayer HealthCare Phar...

Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology

...-CLL. Campath was initially approved in 2001 under accelerated approval regulations for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy. Campath was developed by Genzyme Corporation. Campath is marketed in the U.S. by Bayer HealthCare Ph...

Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting

...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...

Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting

...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...

Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting

...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...

Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine

...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...

Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML

...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...

AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma

...mage and apoptosis. In preclinical in vitro and animal model studies it shows activity against human tumors including melanoma and is synergistic with alkylating agents including dacarbazine. Fifty (50) patients were treated with Amplimexon at MTD (maximum tolerated dose) during the Phase II portion of the tr...
Alkylating in Biological News

Researchers reveal structure of protein that repairs damage to cancer cells

...me strategy to all kinds of other protein-DNA complexes. The AlkB and ABH2 proteins repair alkylation damage to DNA, including the damage caused by alkylating cancer treatments. Alkylation is the addition of certain chemical groups to DNA and is particularly harmful to rapidly growing cells such as cancerous...
Alkylating in Biological Technology

Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma

...iate treatment, never progress beyond the early stages of the disease. About Clearazide Clearazide is a topical form of nitrogen mustard, an alkylating agent that works by inhibiting DNA replication. Nitrogen mustard has also demonstrated activity in other T-cell proliferating diseases such as psoria...

Telik Reports Preclinical Results at AACR Annual Meeting

...hanism of TLK58747; Abstract # 4515 Telik researchers identified a novel alkylating agent, TLK58747, which functions as a prodrug, without the need for enzymat...lease an activation byproduct known to be associated with toxicity of other alkylating agents (acrolein). Key findings: TLK58747 inhibited th...

Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research

...8:00 to 12:00 p.m. local time on Sunday, April 19, 2009. "The critical role of cleavable linkers for minor groove binding alkylating agent (MGBA) based antibody-drug conjugates" (Abstract #1722), S. Gangwar - Poster presentation from 1:00 to 5:00 p.m. local time on Sunday, April 19,...

Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)

...pulation particularly attractive." About Onrigin Onrigin (laromustine) Injection, formerly known as Cloretazine(R) (VNP40101M), is a novel alkylating agent. Onrigin has been evaluated in over 800 patients in 16 clinical trials to date, including a pivotal Phase II trial in patients sixty years of ag...

Medarex Announces Allowance of Investigational New Drug Application for Company's First Antibody-Drug Conjugate, MDX-1203

...platform. Medarex's proprietary ADC technology uses a cytotoxic agent that is a potent, synthetically manufactured prodrug (a DNA minor-groove binding alkylating agent) which is attached to an antibody using a stable peptide-based linker. Medarex believes that its ADC technology overcomes many of the key develo...

Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting

...vative cancer therapeutics. Vion has two agents in clinical trials. Onrigin(TM) (laromustine), formerly known as Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelog...

Vion Reports 2008 First Quarter Results

...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...

Vion Pharmaceuticals Files Plan With Nasdaq

...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...

Vion Reports 2007 Fourth Quarter and Year-End Results

...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogen...

Vion Pharmaceuticals to Host Conference Call to Discuss 2007 Fourth Quarter and Year-End Financial Results

...rldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a pivotal Phase II trial as a single agent in elderly patients with de novo poor-risk acute myelogenous leukemia. Clinica...
Alkylating in Biological Dictionary

Alkylating agents

...ation, a free radical, a carbanion or a carbene . alkylating agents are widely used in chemistry... An alkylating antineoplastic agent is an alkylating agent used in cancer treatment that attaches an...
Other Tags
(Date:7/10/2014)... Harbor, NY For decades, health-conscious people around the ... in antioxidants, figuring this was one of the paths ... , Yet clinical trials of antioxidant supplements have repeatedly ... to reduce their cancer risk. Virtually all such ... cancer. In fact, in several trials antioxidant supplementation ...
(Date:7/10/2014)... at sarcomas research group at the Bellvitge Biomedical Research ... have been tested in 19 patients a new therapeutic ... which indicate that the new treatment could stabilize the ... in the British Journal of Cancer ., ... and complex since there are several subtypes. It can ...
(Date:7/10/2014)... a new drug could prove useful in treating small cell ... , Scientists from the Cancer Research UK Manchester Institute, based ... Cancer Research Centre, teamed up with experts at AstraZeneca, as ... drug known as AZD3965 - on small cell lung ... Clinical Cancer Research , also helps identify which patients are ...
(Date:7/9/2014)... WASHINGTON, DC (July 10, 2014) If you think winning ... fun for kids think again: Winning along with other mental ... each of which falls into one of 11 big fun ... that winning is all important when it comes to the ... identify and quantify what goes into this elusive conceptuntil now. ...
(Date:7/9/2014)... of low back pain are not linked to weather ... and precipitation. Findings published in Arthritis Care & ... Rheumatology (ACR), indicate that the risk of low back ... gusts, but was not clinically significant. , According ... low back pain at some point in their life, ...
Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Low back pain? Don't blame the weather 2
(Date:7/10/2014)... and teens living with a cardiac pacemaker, a low ... of life, reports a study in the July ... the official journal of the Society for Developmental ... by Lippincott Williams & Wilkins , a part ... function as a protective factor against lower health-related quality ...
(Date:7/10/2014)... image was collected by the Moderate Resolution Imaging Spectroradiometer ... Each hot spot, which appears as a red mark, ... MODIS instrument recognized temperatures higher than background. When accompanied ... hot spots are diagnostic for fire. , This ... coming directly from the fires, although the smoke released ...
(Date:7/10/2014)... some patients, the chronic inflammatory skin diseases psoriasis* and ... have therefore had to base their decision on which ... an examination of tissue samples. A team of researchers ... of Munich (TUM) have now analyzed the molecular processes ... This has enabled them for the first time to ...
Breaking Biology News(10 mins):For children with pacemakers, 'self-competence' affects quality of life 2New diagnostic test to distinguish psoriasis from eczema 2
Other Contents